{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T13:27:16Z","timestamp":1791120436649,"version":"4.1.0"},"reference-count":47,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2012,7,16]],"date-time":"2012-07-16T00:00:00Z","timestamp":1342396800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0040853","type":"journal-article","created":{"date-parts":[[2012,7,19]],"date-time":"2012-07-19T04:01:45Z","timestamp":1342670505000},"page":"e40853","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":21,"title":["Intracellular Retention of ABL Kinase Inhibitors Determines Commitment to Apoptosis in CML Cells"],"prefix":"10.1371","volume":"7","author":[{"given":"Daniel B.","family":"Lipka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Christine","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Dziadosz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Schn\u00f6der","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Heidel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirle","family":"Schemionek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junia V.","family":"Melo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kindler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"M\u00fcller-Tidow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Koschmieder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2012,7,16]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia.","volume":"23","author":"A Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"5089","DOI":"10.1182\/blood-2010-04-261867","article-title":"FLT3 as a therapeutic target in AML: still challenging after all these years.","volume":"116","author":"T Kindler","year":"2010","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.","volume":"363","author":"S Verstovsek","year":"2010","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1200\/JCO.2010.32.8021","article-title":"Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis.","volume":"29","author":"A Pardanani","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/jnci\/91.2.163","article-title":"In vivo eradication of human BCR\/ABL-positive leukemia cells with an ABL kinase inhibitor.","volume":"91","author":"P le Coutre","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study.","volume":"111","author":"RA Larson","year":"2008","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","article-title":"Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia.","volume":"109","author":"S Picard","year":"2007","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.","volume":"344","author":"BJ Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.","volume":"354","author":"M Talpaz","year":"2006","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","article-title":"Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.","volume":"26","author":"NP Shah","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3324\/haematol.2009.011452","article-title":"Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib.","volume":"95","author":"NP Shah","year":"2010","journal-title":"Haematologica"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ccr.2008.11.001","article-title":"Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis.","volume":"14","author":"NP Shah","year":"2008","journal-title":"Cancer Cell"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1182\/blood-2007-10-113969","article-title":"Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis.","volume":"114","author":"JL Snead","year":"2009","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/leu.2009.45","article-title":"Short-term intense Bcr-Abl kinase inhibition with nilotinib is adequate to trigger cell death in BCR-ABL(+) cells.","volume":"23","author":"DK Hiwase","year":"2009","journal-title":"Leukemia"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/onc.2009.374","article-title":"Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-gamma1-driven activation of mTOR\/p70S6-kinase pathway.","volume":"29","author":"B Markova","year":"2010","journal-title":"Oncogene"},{"key":"ref16","first-page":"825","article-title":"Daunorubicin uptake by leukemic cells: correlations with treatment outcome and mdr1 expression.","volume":"7","author":"JP Marie","year":"1993","journal-title":"Leukemia"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1182\/blood-2004-04-1566","article-title":"Increased expression of the Abcg2 transporter during erythroid maturation plays a role in decreasing cellular protoporphyrin IX levels.","volume":"105","author":"S Zhou","year":"2005","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/sj.leu.2402940","article-title":"In BCR-ABL-positive cells, STAT-5 tyrosine-phosphorylation integrates signals induced by imatinib mesylate and Ara-C.","volume":"17","author":"T Kindler","year":"2003","journal-title":"Leukemia"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cell.2004.06.028","article-title":"Single Cell Profiling of Potentiated Phospho-Protein Networks in Cancer Cells.","volume":"118","author":"JM Irish","year":"2004","journal-title":"Cell"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor.","volume":"305","author":"NP Shah","year":"2004","journal-title":"Science"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/jm049486a","article-title":"Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays.","volume":"47","author":"LJ Lombardo","year":"2004","journal-title":"J Med Chem"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1182\/blood-2006-02-003145","article-title":"Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate.","volume":"108","author":"NE Jordanides","year":"2006","journal-title":"Blood"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/nm0901-1028","article-title":"The ABC transporter Bcrp1\/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype.","volume":"7","author":"S Zhou","year":"2001","journal-title":"Nat Med"},{"key":"ref24","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2010-07-296954","article-title":"Polymorphisms in the multidrug resistance gene MDR1 (ABCB1) predict for molecular resistance in patients with newly diagnosed chronic myeloid leukemia receiving high-dose imatinib.","author":"W Deenik","year":"2010"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1182\/blood.V101.6.2368","article-title":"MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models.","volume":"101","author":"FX Mahon","year":"2003","journal-title":"Blood"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/sj.leu.2404638","article-title":"Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells.","volume":"21","author":"C Brendel","year":"2007","journal-title":"Leukemia"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s12032-010-9456-9","article-title":"Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia.","volume":"28","author":"LN Ni","year":"2011","journal-title":"Med Oncol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/sj.leu.2403257","article-title":"P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate.","volume":"18","author":"T Illmer","year":"2004","journal-title":"Leukemia"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/leu.2010.287","article-title":"Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia.","volume":"25","author":"A Samanta","year":"2011","journal-title":"Leukemia"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"7045","DOI":"10.1158\/0008-5472.CAN-06-4312","article-title":"BCR-tyrosine 177 plays an essential role in Ras and Akt activation and in human hematopoietic progenitor transformation in chronic myelogenous leukemia.","volume":"67","author":"S Chu","year":"2007","journal-title":"Cancer Res"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1128\/MCB.13.3.1728","article-title":"SH1 domain autophosphorylation of P210 BCR\/ABL is required for transformation but not growth factor independence.","volume":"13","author":"AM Pendergast","year":"1993","journal-title":"Mol Cell Biol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1084\/jem.189.8.1229","article-title":"Signal transducer and activator of transcription (STAT)5 activation by BCR\/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR\/ABL and is required for leukemogenesis.","volume":"189","author":"M Nieborowska-Skorska","year":"1999","journal-title":"J Exp Med"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S1535-6108(02)00074-0","article-title":"Critical role for Gab2 in transformation by BCR\/ABL.","volume":"1","author":"M Sattler","year":"2002","journal-title":"Cancer Cell"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0092-8674(02)00623-2","article-title":"Autoinhibition of c-Abl.","volume":"108","author":"H Pluk","year":"2002","journal-title":"Cell"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"8075","DOI":"10.1038\/sj.onc.1205017","article-title":"Phosphorylation and structure-based functional studies reveal a positive and a negative role for the activation loop of the c-Abl tyrosine kinase.","volume":"20","author":"K Dorey","year":"2001","journal-title":"Oncogene"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"35631","DOI":"10.1074\/jbc.M005401200","article-title":"c-Abl has high intrinsic tyrosine kinase activity that is stimulated by mutation of the Src homology 3 domain and by autophosphorylation at two distinct regulatory tyrosines.","volume":"275","author":"BB Brasher","year":"2000","journal-title":"J Biol Chem"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1182\/blood-2005-08-3087","article-title":"Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML).","volume":"107","author":"M Scherr","year":"2006","journal-title":"Blood"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/blood-2005-09-3596","article-title":"Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation.","volume":"107","author":"A Hoelbl","year":"2006","journal-title":"Blood"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/emmm.201000062","article-title":"Stat5 is indispensable for the maintenance of bcr\/abl-positive leukaemia.","volume":"2","author":"A Hoelbl","year":"2010","journal-title":"EMBO Mol Med"},{"key":"ref40","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2011-12-397554","article-title":"Essential role for Stat5a\/b in myeloproliferative neoplasms induced by BCR-ABL1 and Jak2V617F in mice.","author":"C Walz","year":"2012"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00280-003-0741-6","article-title":"Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588.","volume":"53","author":"P le Coutre","year":"2004","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","article-title":"Active transport of imatinib into and out of cells: implications for drug resistance.","volume":"104","author":"J Thomas","year":"2004","journal-title":"Blood"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2005-11-4687","article-title":"OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib.","volume":"108","author":"DL White","year":"2006","journal-title":"Blood"},{"key":"ref44","article-title":"Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomised to high-dose imatinib achieve better responses, and lower failure rates, than those randomized to standard-dose.","author":"DL White","year":"2011"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1038\/leu.2009.166","article-title":"Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters.","volume":"23","author":"A Davies","year":"2009","journal-title":"Leukemia"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1182\/blood-2007-10-116236","article-title":"Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia.","volume":"112","author":"A Giannoudis","year":"2008","journal-title":"Blood"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00277-011-1311-3","article-title":"3,4-Diarylmaleimides-a novel class of kinase inhibitors-effectively induce apoptosis in FLT3-ITD-dependent cells.","volume":"91","author":"FH Heidel","year":"2012","journal-title":"Ann Hematol"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0040853","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,26]],"date-time":"2018-10-26T00:19:47Z","timestamp":1540513187000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0040853"}},"subtitle":[],"editor":[{"given":"Alan P.","family":"Fields","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2012,7,16]]},"references-count":47,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2012,7,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0040853","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,16]]}}}